Unknown

Dataset Information

0

Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.


ABSTRACT: Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative disorders that are manageable by immunotherapy. Twenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-gamma] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type. Repeated intralesional therapy using TG1042 consistently results in local tumor regressions in about half of treated patients and one-third of patients also in regressions in noninjected distant lesions, likely reflecting the systemic immune activation after intralesional therapy. Treatment was well tolerated with few adverse events including injection site reactions, chills, lymphopenia, and fever. Immune monitoring in the peripheral blood demonstrated systemic immune activation and the induction of antibodies against tumor antigens in some patients without clear association with clinical responses. CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy.

SUBMITTER: Dummer R 

PROVIDER: S-EPMC2889748 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.

Dummer Reinhard R   Eichmüller Stefan S   Gellrich Sylke S   Assaf Chalid C   Dreno Brigitte B   Schiller Meinhard M   Dereure Olivier O   Baudard Marion M   Bagot Martine M   Khammari Amir A   Bleuzen Pascal P   Bataille Vincent V   Derbij Anna A   Wiedemann Nicole N   Waterboer Tim T   Lusky Monika M   Acres Bruce B   Urosevic-Maiwald Mirjana M  

Molecular therapy : the journal of the American Society of Gene Therapy 20100406 6


Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative disorders that are manageable by immunotherapy. Twenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-gamma] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type. Repeated intralesional therapy using TG1042 consistently results in local tumor regressions in abo  ...[more]

Similar Datasets

| S-EPMC3933342 | biostudies-literature
| S-EPMC7156460 | biostudies-literature
| S-EPMC9358781 | biostudies-literature
| S-EPMC1964512 | biostudies-literature
| S-EPMC3943317 | biostudies-literature
| S-EPMC4965697 | biostudies-literature
| S-EPMC4940438 | biostudies-literature
| S-EPMC5037033 | biostudies-literature
| S-EPMC3865085 | biostudies-literature
| S-EPMC5413429 | biostudies-literature